These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9754432)

  • 1. [Fluctuations in Guillain-Barré syndrome related with intravenous human immunoglobulin (triphasic course): case report].
    Dourado ME; De Freitas ML; Dos Santos FM
    Arq Neuropsiquiatr; 1998 Sep; 56(3A):476-9. PubMed ID: 9754432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid recovery of a child with Guillain-Barré syndrome using intravenous immunoglobulins.
    Shah M; Weinberger M
    J La State Med Soc; 1998 Nov; 150(11):533-7. PubMed ID: 9861805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome.
    Abd-Allah SA; Jansen PW; Ashwal S; Perkin RM
    J Child Neurol; 1997 Sep; 12(6):376-80. PubMed ID: 9309521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of Guillain-Barré syndrome treated with intravenous high doses of immunoglobulins].
    Mauro G
    Rev Neurol (Paris); 1989; 145(10):731-2. PubMed ID: 2510231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guillain-Barré syndrome in children treated with intravenous immunoglobulin].
    Andersen UM
    Ugeskr Laeger; 1993 Oct; 155(42):3392-4. PubMed ID: 8259633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
    Notarangelo LD; Duse M; Tiberti S; Guarneri B; Brunori A; Negrini A; Ugazio AG
    Eur J Pediatr; 1993 Apr; 152(4):372-4. PubMed ID: 8482293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS).
    Shalman A; Savir S; Mechnik Steen Y; Ovanyan A; Boniel N; Koyfman L; Bichovsky Y; Zlotnik A; Klein M; Brotfain E
    J Clin Neurosci; 2020 Apr; 74():247-249. PubMed ID: 32088107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immune globulin in the Guillain-Barré syndrome.
    van der Meché FG
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):43-7. PubMed ID: 8033434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras.
    Koul R; Chacko A; Ahmed R; Varghese T; Javed H; Al-Lamki Z
    J Child Neurol; 2003 Nov; 18(11):767-71. PubMed ID: 14696904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin treatment successfully improved subacute progressive polyradiculoneuropathy with polyclonal gammopathy.
    Endo K; Suzuki N; Ikenishi T; Aoki M; Itoyama Y
    Intern Med; 2009; 48(23):2037-9. PubMed ID: 19952488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
    Visser LH; van der Meché FG; Meulstee J; van Doorn PA
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin.
    Buzzigoli SB; Genovesi M; Lambelet P; Logi C; Raffaelli S; Cattano D
    Anaesth Intensive Care; 2010 Mar; 38(2):387-9. PubMed ID: 20369779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous immunoglobulin in children with Guillain-Barré syndrome].
    Bruck I; Antoniuk SA; Cat R; Spessatto A; Halick SM; Bruyn LR; Rodrigues M; Scola RH; Werneck LC
    Arq Neuropsiquiatr; 2000 Dec; 58(4):1081-91. PubMed ID: 11105076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome'.
    Manonmani V; Ouvrier R
    Dev Med Child Neurol; 1997 Jun; 39(6):425. PubMed ID: 9233371
    [No Abstract]   [Full Text] [Related]  

  • 18. [High-dose immunoglobulins in children with Guillain-Barré syndrome].
    Shahar E; Brand N
    Harefuah; 1991 Oct; 121(7-8):225-8. PubMed ID: 1783308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin.
    Sater RA; Rostami A
    Neurology; 1998 Dec; 51(6 Suppl 5):S9-15. PubMed ID: 9851724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.
    Fokkink WJR; van Tilburg SJ; de Winter BCM; Sassen SDT; van Doorn PA; Koch BCP; Jacobs BC
    Clin Pharmacokinet; 2022 Sep; 61(9):1285-1296. PubMed ID: 35781631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.